Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Neurocrine is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for neurological and endocrine-related diseases. The company has no approved products and generates revenue primarily through collaboration agreements, license fees, and milestone payments. Key programs include elagolix (endometriosis), CRF antagonists (mood disorders), and indiplon (insomnia).
Key Financial Metrics
| Metric (in thousands) | 2009 | 2008 |
|---|---|---|
| Total Revenues | $2,953 | $3,975 |
| Net Loss | $(51,038) | $(88,613) |
| Loss Per Share (Basic/Diluted) | $(1.30) | $(2.30) |
| Research & Development Expenses | $35,810 | $55,291 |
| General & Administrative Expenses | $14,829 | $20,240 |
| Cash, Cash Equivalents & Investments | $53,464 | $80,473 |
| Working Capital | $35,426 | $55,329 |
| Accumulated Deficit | $(754,301) | $(703,263) |
| Long-term Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 26% to $2.95 million in 2009 from $3.98 million in 2008. This was primarily due to the absence of a $1.0 million milestone payment recognized in 2008 under the GlaxoSmithKline (GSK) collaboration agreement.
- Reduced Net Loss: Net loss improved significantly to $51.0 million in 2009 from $88.6 million in 2008. This improvement was driven by cost containment efforts, staff reductions (approximately 65 employees in 2009), and lower external development costs.
- R&D Expense Reduction: R&D expenses dropped by $19.5 million (35%) to $35.8 million, attributed to personnel cost savings ($5.8 million) and reduced external development costs ($9.4 million), particularly for the GnRH clinical program.
- Real Estate Restructuring: The company recognized $6.0 million in cease-use expense in 2009 related to the front building of its corporate headquarters, compared to $15.7 million in 2008. In September 2009, the company entered a second lease amendment to vacate the front building, paying a $4.0 million release fee.
Guidance, Outlook, and Risks
- Profitability Outlook: Management does not expect to be profitable in 2010 or the foreseeable future. The company anticipates continued operating losses and negative cash flow as it advances clinical programs.
- Liquidity: As of December 31, 2009, the company held $53.5 million in cash and investments. Management believes existing resources, combined with investment income and future collaboration payments, are sufficient to fund operations for at least the next 12 months.
- Financing Facilities: The company has a Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Limited for up to $75 million and an effective shelf registration statement for up to $140 million in equity offerings.
- Key Risks:
- Indiplon Uncertainty: The insomnia drug candidate indiplon received an "approvable" letter from the FDA in 2007 but requires additional studies (elderly trial, safety study, pregnancy study). The company has ceased U.S. development activities and is evaluating alternatives.
- Elagolix Development: The lead candidate for endometriosis is in Phase II. The company expects to submit a Phase III protocol to the FDA in mid-2010 but does not intend to initiate Phase III trials until a partnership is secured.
- Auction Rate Securities: Approximately $20.4 million (par value) of investments are in illiquid auction rate securities. While currently valued at $18.0 million, liquidity is constrained, and access to these funds may result in a loss of principal.
Investor Verification Checklist
- Indiplon Status: Verify the current status of the FDA requirements for indiplon and whether the company has secured a partner to fund the required additional studies.
- Elagolix Partnership: Confirm if a commercial partner has been identified for the elagolix program, as Phase III initiation is contingent on this.
- Liquidity Runway: Monitor cash burn rates and the utilization of the CEFF or shelf registration to ensure the 12-month liquidity projection remains valid.
- Auction Rate Securities: Review the valuation assumptions and liquidity status of the $18.0 million auction rate securities portfolio, specifically the exercise period for the UBS ARS Rights beginning June 30, 2010.
- Lease Obligations: Assess the impact of the remaining lease obligations for the rear building and the rent differential payments for the vacated front building through 2019.